Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dengue virus serotype 2 expressing dengue virus serotype 3 surface proteins, live attenuated
- Development stage
- Unknown
- Lead developer
- Umeå University
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
dengue virus serotype 2 expressing dengue virus serotype 3 surface proteins, live attenuated is a monovalent, live-attenuated chimeric vaccine candidate developed for the prevention of dengue fever caused by serotype 3. The vaccine utilizes a recombinant technology where the genetic backbone of an attenuated dengue virus serotype 2 (DENV-2) is modified to express the pre-membrane (prM) and envelope (E) structural proteins of dengue virus serotype 3 (DENV-3). This chimeric structure allows the virus to maintain the attenuation characteristics of the DENV-2 parent while presenting the critical neutralizing epitopes of DENV-3 to the host immune system. Developed in part through research at Umea University and sponsored by Region Vaesterbotten, this candidate has been evaluated in Phase 1 clinical trials to determine its safety and ability to induce serotype-specific neutralizing antibodies in flavivirus-naive populations.
- Other names
- chimeric DENV-2/3 vaccineDENV-2/3
02
Targets
Human B-cell receptor recognizing dengue virus serotype 3 envelope protein
Beyond the preview
Go deeper on dengue virus serotype 2 expressing dengue virus serotype 3 surface proteins, live attenuated.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dengue virus serotype 2 expressing dengue virus serotype 3 surface proteins, live attenuated.